PTT-621
/ Pyrotech Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 06, 2026
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis
(clinicaltrials.gov)
- P2 | N=40 | Not yet recruiting | Sponsor: Pyrotech Therapeutics, Inc.
New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
October 31, 2025
A single-center, randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of single and multiple dosing of PTT-621 in healthy patients
(ChiCTR)
- P1 | N=84 | Recruiting | Sponsor: Peking University Third Hospital; Pyrotech (Beijing) Biotechnology Co., Ltd
New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease
1 to 2
Of
2
Go to page
1